Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Imaging Biol ; 18(1): 117-26, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26013478

ABSTRACT

PURPOSE: The first biological evaluation of two potent fluorine-18 radiolabelled inhibitors of caspase-3/7 was achieved in a cerebral stroke rat model to visualize apoptosis. PROCEDURES: In vivo characteristics of isatins [(18)F]-2 and [(18)F]-3 were studied and compared by µPET to previously described 1-[4-(2-[(18)F]fluoroethyl)benzyl]-5-(2-methoxymethylpyrrolidin-1-ylsulfonyl)isatin ([(18)F]-1) and to 2-(5-[(18)F]fluoropentyl)-2-methyl-malonic acid ([(18)F]ML-10) used as a reference radiotracer in a rat stroke model. RESULTS: [(18)F]-2 and [(18)F]-3 were radiolabelled with high radiochemical purity and high specific radioactivity. Radioactivity uptakes in ischemic and contralateral brain regions were weak for the three radiolabelled isatins and lower for [(18)F]ML-10. In µPET, time activity curves showed significant uptake differences between both regions of interest for [(18)F]-1 after 45 min. No differences were observed for [(18)F]ML-10. CONCLUSIONS: Radiolabelled isatins are more promising radiotracers to image apoptosis than [(18)F]ML-10 in this stroke animal model without craniectomy. In particular, [(18)F]-1 presented significant uptake in apoptotic area 45 min after administration.


Subject(s)
Apoptosis/drug effects , Caspase 3/metabolism , Caspase 7/metabolism , Caspase Inhibitors/pharmacology , Methylmalonic Acid/analogs & derivatives , Molecular Imaging/methods , Radiopharmaceuticals/pharmacology , Stroke/diagnostic imaging , Animals , Caspase Inhibitors/blood , Caspase Inhibitors/pharmacokinetics , Disease Models, Animal , Isatin/chemistry , Isatin/pharmacology , Male , Methylmalonic Acid/pharmacokinetics , Methylmalonic Acid/pharmacology , Radionuclide Imaging , Radiopharmaceuticals/blood , Radiopharmaceuticals/pharmacokinetics , Rats, Sprague-Dawley , Stroke/pathology , Tissue Distribution/drug effects
2.
Regul Toxicol Pharmacol ; 72(2): 169-78, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25896096

ABSTRACT

Emricasan, formerly IDN-6556, is a small molecule currently being evaluated in clinical trials to reduce hepatic injury and liver fibrosis. Since emricasan is an irreversible pan-caspase inhibitor that potently inhibits caspase-mediated apoptosis and inflammation, its carcinogenic potential was evaluated in a humanized mouse model. Tg.rasH2 mice received LabDiet formulated with 0, 10, 25, and 75mg/kg/day of emricasan, for 26weeks. At terminal sacrifice, blood was collected for clinical pathology analysis and tissues were collected, processed, and evaluated microscopically. There were no treatment related deaths or overt signs of toxicity for the duration of the study. There was no evidence of a carcinogenic effect in the peripheral blood leukocyte counts. Liver microgranulomas, which are background lesions, were slightly increased, especially in males. Increases in the incidence of the activated germinal centers were seen in the spleens and mesenteric lymph nodes of males and females, and in the mandibular lymph nodes of male mice. Atrophy of ovaries and testicular degeneration were also seen in emricasan treated animals. Although several non-neoplastic lesions were observed, there was no evidence of emricasan-related tumor formation in any tissue. In addition, the non-neoplastic lesions were not considered pre-neoplastic. Thus, emricasan is not considered carcinogenic.


Subject(s)
Caspase Inhibitors/toxicity , Pentanoic Acids/toxicity , Animals , Carcinogenicity Tests , Caspase Inhibitors/blood , Caspase Inhibitors/pharmacokinetics , Female , Genes, ras , Granuloma/chemically induced , Liver/drug effects , Liver/pathology , Lung/anatomy & histology , Lung/drug effects , Male , Mice, Transgenic , Ovary/drug effects , Ovary/pathology , Pentanoic Acids/blood , Pentanoic Acids/pharmacokinetics , Spleen/anatomy & histology , Spleen/drug effects , Testis/drug effects , Testis/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...